| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 07/10/2003 | US20030130214 Proteins, compositions, diagnostic and therapeutic uses thereof |
| 07/10/2003 | US20030130209 Method of treatment of myocardial infarction |
| 07/10/2003 | US20030130187 Porcine adenovirus type 3 genome |
| 07/10/2003 | US20030130186 Conjugates and compositions for cellular delivery |
| 07/10/2003 | US20030130184 Using protein from papilloma virus; genetic engineering |
| 07/10/2003 | US20030129750 Inducing vascular growth in tissue via administration of cytokine, chemokine, or chemoattractant; for treatment of cardiac ischemia; tissue engineering |
| 07/10/2003 | US20030129733 Inactivated genomes of diploid microorganisms which are inducible into haploid forms; drug screening |
| 07/10/2003 | US20030129728 Disrupting genes and mixing with plasmids/DNA vaccine; immunology; gene therapy; aging resistance |
| 07/10/2003 | US20030129725 Zace1: a human metalloenzyme |
| 07/10/2003 | US20030129722 Comprises phospholipid scramblase phosphorylated by protein kinases; antithrombotic agents |
| 07/10/2003 | US20030129706 Fhm, a novel member of the TNF ligand supergene family |
| 07/10/2003 | US20030129702 DNA encoding galanin GALR2 receptors and uses thereof |
| 07/10/2003 | US20030129698 Involved in homo and heterotrimerization or oligomerization |
| 07/10/2003 | US20030129696 Polynucleotides and polypeptides encoding receptors |
| 07/10/2003 | US20030129688 Heregulin variants |
| 07/10/2003 | US20030129687 Keratinocyte growth factor-2 |
| 07/10/2003 | US20030129686 Novel nucleic acid and polypeptide molecules |
| 07/10/2003 | US20030129678 Methods, pharmaceutical formulations and kits for identification of subjects at risk for cancer |
| 07/10/2003 | US20030129645 Can be used as models for the development of human therapeutic targets, aid in the identification of therapeutic proteins, and serve as targets for the development of human therapeutic agents that modulate kinase activity |
| 07/10/2003 | US20030129606 Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases |
| 07/10/2003 | US20030129597 Inhibiting EG-1 to inhibit angiogenesis and metastasis |
| 07/10/2003 | US20030129596 Chemical compounds |
| 07/10/2003 | US20030129251 Polynucleotide of an immunostimulatory sequence linked to a biodegradable microcarrier |
| 07/10/2003 | US20030129221 A mixture of lipids containing a protonatable or deprotonatable lipid, such as polyoxyethylene glycol or polyamide oligomer modified lipid, or amino lipid is combined with a buffered aqueous solution of a charged drug |
| 07/10/2003 | US20030129202 Mutated hepatitis b virus, its nucleic and protein constituents and uses thereof |
| 07/10/2003 | US20030129190 FX activity in cells in cancer, inflammatory responses and diseases and in autoimmunity |
| 07/10/2003 | US20030129189 Angiogenesis inhibitors for treament of inflammation, cachexia, septic shock, cerebral malaria, arthritis, and graft-rejection |
| 07/10/2003 | US20030129175 Gene therapy; heterogeneity tissue transcription; antitumor agents |
| 07/10/2003 | US20030129174 Antihemophilic factor; insertion of culture product into blood; polypeptide |
| 07/10/2003 | US20030129172 Animal growth regulator |
| 07/10/2003 | US20030129171 Cloning mastitis gene; muscular disorders |
| 07/10/2003 | US20030129170 Central nervous system disorders; antidiabetic agents |
| 07/10/2003 | US20030129169 Novel expression vectors and uses thereof |
| 07/10/2003 | US20030129168 Expression of proteins for treating asthma via ligand mediated activation of their encoding genes |
| 07/10/2003 | US20030129164 Expression of glial-derived neurotrophic factor for treatment of diseases of the eye |
| 07/10/2003 | CA2473728A1 Methods of modulating heme oxygenase-1 expression and treating heme oxygenase-1 mediated conditions |
| 07/10/2003 | CA2471385A1 Preventives/remedies for cancer |
| 07/10/2003 | CA2471306A1 Secreted proteins |
| 07/10/2003 | CA2471297A1 Human netrin receptor and uses thereof |
| 07/10/2003 | CA2471130A1 Il-17 like molecules and uses thereof |
| 07/10/2003 | CA2471035A1 Knockout swine and methods for making the same |
| 07/10/2003 | CA2470903A1 A system for stable expression of sirnas in mammalian cells |
| 07/10/2003 | CA2470666A1 Secreted protein |
| 07/10/2003 | CA2469690A1 Beta-amyloid binding factors and inhibitors thereof |
| 07/09/2003 | EP1325960A2 Negative strand RNA virus vector having autonomously replicating activity |
| 07/09/2003 | EP1325930A1 Mammal prolactin variants |
| 07/09/2003 | EP1325929A2 Cytotoxic cyplasin of the sea hare, Aplysia punctata, cDNA cloning and expression of bioreactive recombinants |
| 07/09/2003 | EP1325751A1 Novel drugs for liver diseases |
| 07/09/2003 | EP1325338A2 Diagnosis and treatment of alzheimer's disease |
| 07/09/2003 | EP1325145A1 Adenoviral vectors for gene delivery in skeletal muscle cells or myoblasts |
| 07/09/2003 | EP1325144A2 Chromosomal vectors and uses thereof |
| 07/09/2003 | EP1325138A2 Optimized messenger rna |
| 07/09/2003 | EP1325129A2 Identification of a new cytotoxic activity from the ink of aplysia punctata |
| 07/09/2003 | EP1325128A2 Lipocalins |
| 07/09/2003 | EP1325125A2 Chromosome 3p21.3 genes are tumor suppressors |
| 07/09/2003 | EP1325124A2 Clk-2, cex-7 and coq-4 genes, and uses thereof |
| 07/09/2003 | EP1325122A2 Modulation of the transcription of pro-inflammatory gene products |
| 07/09/2003 | EP1325116A2 Isoprenoid-dependent ras anchorage (idra) proteins |
| 07/09/2003 | EP1325112A2 Methods of isolating bipotent hepatic progenitor cells |
| 07/09/2003 | EP1325030A2 Genes isolated from dendritic cells, gene products and methods employing the same |
| 07/09/2003 | EP1325028A2 New inhibitors of iapp fibril formation and uses thereof |
| 07/09/2003 | EP1325025A1 Peptide-based gemini surfactant compounds facilitating the transfer into cells |
| 07/09/2003 | EP1325021A1 12 human secreted proteins |
| 07/09/2003 | EP1325020A1 21 human secreted proteins |
| 07/09/2003 | EP1325019A1 Antisense modulation of clusterin expression |
| 07/09/2003 | EP1325018A1 Antisense modulation of her-2 expression |
| 07/09/2003 | EP1324780A2 Cardiac arrhythmia treatment methods |
| 07/09/2003 | EP1324772A2 Methods for treating disorders of the female reproductive system |
| 07/09/2003 | EP1324768A2 Vaccines for proliferative ileitis |
| 07/09/2003 | EP1324763A1 Stat3 agonists and antagonists and therapeutic uses thereof |
| 07/09/2003 | EP1324652A2 Transgenic drosophila melanogaster expressing beta amyloid |
| 07/09/2003 | EP1071752B1 CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF |
| 07/09/2003 | EP0788307B1 Oligonucleotide modulation of the expression of multidrug resistance-associated protein |
| 07/09/2003 | EP0686260B1 Human carcinoma antigen (hca), hca antibodies, hca immunoassays, methods of imaging and therapy |
| 07/09/2003 | EP0626012B1 Homogenotization of gene-targeting events |
| 07/09/2003 | EP0619738B1 Inhibitory immunoglobulin polypeptides to human pdgf beta receptor |
| 07/09/2003 | CN1429273A Protection against environmental toxicity through manipulation of processing of messenger RNA precursors |
| 07/09/2003 | CN1429270A Synthetic gagpol genes and their use |
| 07/09/2003 | CN1429268A Novel deoxyribonucleside kinase enzyme multi-substrate variants |
| 07/09/2003 | CN1429073A A gene therapy system and method using alpha-MSH and its derivatives |
| 07/09/2003 | CN1428427A Endoplasmic target polypeptide expression box |
| 07/09/2003 | CN1428426A Programmed cell death induction molecule II |
| 07/08/2003 | US6590090 Isolated DNA comprising nucleotide sequence coding for a protein of given amino acid sequence; useful as prophylactic or therapeutic agents for cancer, viral/bacterial infections, hepatitis, nephritis, bone disease, atherosclerosis or pain |
| 07/08/2003 | US6590086 Mutants of the Rb and p53 genes and uses thereof |
| 07/08/2003 | US6590076 Isolated polypeptide, of given sequence, comprising at least an immunogenic portion of a tumor antigen; may be used to generate antibodies |
| 07/08/2003 | US6589782 VEGF (Vascular Endothelial Growth Factor); adenovirus vector; Use in treating cardiovascular disorders, enhancing the neovascularization of diseased blood vessels and enhancing drug delivery via improved vascular permeability |
| 07/08/2003 | US6589763 Retroviral hybrid vectors pseudotyped with LCMV |
| 07/08/2003 | US6589728 Methods for isolation and activation of, and control of differentiation from, stem and progenitor cells |
| 07/08/2003 | US6589549 Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles |
| 07/08/2003 | US6589531 Recombinant yellow fever virus and method of use thereof |
| 07/08/2003 | US6589523 Agent for gene therapy of dilated cardiomyopathy |
| 07/08/2003 | CA2140428C Novel 2'-o-alkyl nucleosides and phosphoramidites processes for the preparation and uses thereof |
| 07/03/2003 | WO2003054541A2 Inhibition of tristetraproline for protection of the heart from cardiac injuries |
| 07/03/2003 | WO2003054512A2 Identification of an amplified gene and target for drug intervention |
| 07/03/2003 | WO2003054212A2 A method and compositions for conferring viral immunity and reversing viral pathogenesis via strategic infection with a theravirus thereby providing genomic integration of genetically engineered, replication incompetent, integrating viral dna |
| 07/03/2003 | WO2003054197A2 A library of modified structural genes or capsid modified particles useful for the identification of viral clones with desired cell tropism |
| 07/03/2003 | WO2003054195A1 Novel gene useful in diagnosing cancer and use thereof |
| 07/03/2003 | WO2003054165A2 Genetic markers and methods for the diagnosis, treatment and prevention of tumor metastasis |
| 07/03/2003 | WO2003054154A2 Antisense modulation of mucin 1, transmembrane expression |
| 07/03/2003 | WO2003054152A2 Novel nucleic acids and polypeptides |